Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02890888
Other study ID # 2014.011
Secondary ID
Status Terminated
Phase N/A
First received September 5, 2014
Last updated October 25, 2017
Start date November 2014
Est. completion date October 25, 2017

Study information

Verified date October 2017
Source St. Luke's Hospital, Chesterfield, Missouri
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients will have a Functional MRI before and after 10 hyperbaric Oxygen treatments.


Description:

Functional MRI studies will be done before and 4-6 weeks after Hyperbaric Oxygen treatment to assess changes in connectivity of resting state neural networks. 10 hyperbaric treatments at 2 atmospheres absolute for 1 hour at pressure will be administered. A review of symptoms and and thorough clinical neurological examination by an experienced neurologist familiar with these studies will be done before and 4-6 weeks after the hyperbaric treatments.


Recruitment information / eligibility

Status Terminated
Enrollment 6
Est. completion date October 25, 2017
Est. primary completion date October 25, 2017
Accepts healthy volunteers No
Gender All
Age group 50 Years to 90 Years
Eligibility Inclusion Criteria:

- White Matter Hyperintensities on MRI

- 2 or more neurological symptoms or impairments e.g. gait disturbances, disequilibrium, cognitive decline, dysmetria, hyper-rflexia

Exclusion Criteria:

- Contraindication to hyperbaric oxygen treatment e.g. pulmonary emphysema, seizure disorder

- major eustachian tube dysfunction

- stroke with previous 6 months

- extreme cognitive impairment

- major depression

- history of migraine, electroshock therapy, brain irradiation, brain tumor, head trauma

- other uncontrolled co-morbidities, e.g. diabetes, renal or hepatic dysfunction, hypertension, thyroid disorders, carotid artery stenosis (>70%)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
hyperbaric oxygen treatment
Patients are treated in a hyperbaric oxygen chamber for 1 hour at 2ATA, 10 times over 2 consecutive weeks, 5 times per week

Locations

Country Name City State
United States St. Luke's hospital Chesterfield Missouri
United States Mallinckrodt Institute of Radiology/Washington University Medical School Saint Louis Missouri
United States St. Luke's Hospital Saint Louis Missouri

Sponsors (2)

Lead Sponsor Collaborator
St. Luke's Hospital, Chesterfield, Missouri Washington University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in average functional connectivity (fc) within the Default Mode Network and the Dorsal Attention Network will be obtained by resting state network (rsn) functional connectivity (rsnfc) MRI. Functional connectivity MRI of resting state neural networks. Change in baseline rsnfc before and 4 weeks after hyperbaric oxygen
See also
  Status Clinical Trial Phase
Recruiting NCT04041349 - Clinical Observation for the Therapeutic Effect of mNGF on Cognitive Decline in Cerebral Small Vessel Disease Phase 4
Recruiting NCT04109963 - Trial of Remote Ischemic Pre-conditioning in Vascular Cognitive Impairment Phase 2
Not yet recruiting NCT06416371 - Retinal Vessel Leakage in Cerebral Small Vessel Disease
Not yet recruiting NCT05967728 - Testing of a System for Remote Ischemic Conditioning in Cerebral Small Vessel Disease and Pre-hospital Stroke Care Phase 2
Completed NCT05714813 - Circuit Training and Retina N/A
Not yet recruiting NCT06077305 - A Registry Study of Microcirculation Disorder After Cerebral Small Vessel Disease and Ischemic Stroke
Not yet recruiting NCT06061692 - Tongxinluo Capsule in the Treatment of Cerebral Small Vessel Disease-A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study(TOPS-CSVD) Phase 4
Recruiting NCT04962295 - China Imaging-based Biobank of Cerebral Small Vessal Diseases
Completed NCT02801032 - Effect of Tadalafil on Cerebral Large Arteries in Stroke Phase 2
Not yet recruiting NCT05594966 - Neuroimaging Combining Biomarkers for Identifying Long-term Cognitive Dysfunction and Delirium
Recruiting NCT04318119 - Cerebral Small Vessel Disease Registry Study
Recruiting NCT03906123 - The Efficacy of DL-NBP in Patients With Mild Subcortical Ischemic Vascular Dementia N/A
Recruiting NCT05306834 - Stopping Cognitive Decline and Dementia by Fighting Covert Cerebral Small Vessel Disease N/A
Not yet recruiting NCT05583266 - Efficacy of Pentoxifylline on Cerebrovascular Function in Patients With Cerebral Small Vessel Disease(PERFORM) Phase 4
Recruiting NCT05173896 - Improving Cerebral Blood Flow and Cognition in Patients With Cerebral Small Vessel Disease. The ETLAS-2 Trial Phase 2
Recruiting NCT01819441 - Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients Phase 4
Recruiting NCT01688505 - Visit-to-Visit Variability in Blood Pressure as a Predictor of Poor Cognitive Function N/A
Recruiting NCT04330222 - Cambridge 7 Tesla Cerebral Small Vessel Disease Study
Recruiting NCT04298866 - White Matter Hyperintensities Subtypes in Cerebral Small Vessel Disease : 7 Tesla Ultra-high Resolution Imaging MRI N/A
Not yet recruiting NCT06319495 - Stellate Ganglion Block in Patients With Cerebral Small Vessel Disease N/A